GlassScriptPhysician profile
Loida Bonney
NPI 1316998982
$2,051.86
in general payments reported to CMS, 2019-2025
22 companies · $382 in 2025
The $382 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $40.71 · 2021: $52.02 · 2022: $300 · 2023: $455 · 2024: $613 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,449.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,449.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $331.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $259.01 | 2019-2024 | Veozah |
| Pfizer INC. | $244.29 | 2022-2025 | |
| Abbvie INC. | $157.84 | 2023-2025 | Vraylar, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $132.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $121.00 | 2022-2024 | Arexvy, Shingrix |
| Lilly USA, LLC | $102.53 | 2022-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.99 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $74.19 | 2022-2023 | |
| Amgen INC. | $70.58 | 2022-2024 | Otezla, Repatha, Krystexxa |
| Sumitomo Pharma America, INC. | $69.58 | 2024-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $60.65 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $56.74 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $56.30 | 2023-2024 | Spravato |
| Astrazeneca Pharmaceuticals LP | $52.88 | 2023-2025 | Farxiga, Airsupra, Breztri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $35.72 | 2021 | |
| Merck Sharp & Dohme LLC | $34.24 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Daiichi Sankyo INC. | $27.66 | 2023 | Injectafer |
| Globus Medical, INC. | $23.10 | 2025 | Senza |
| Exact Sciences Corporation | $20.06 | 2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.00 | 2024 | Caplyta |
| Dexcom, INC. | $14.99 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loida Bonney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.